Sarepta Therapeutics (SRPT) Other Accumulated Expenses (2010 - 2026)

Sarepta Therapeutics' Other Accumulated Expenses history runs 17 years deep, the most recent figure standing at $4.6 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 70.43% year-over-year to $4.6 million in Q1 2026; TTM through Mar 2026 was $4.6 million, a 70.43% decrease from a year earlier, with the FY2025 full-year figure at $7.0 million, down 48.3% from the prior year.
• Other Accumulated Expenses eased to $4.6 million in Q1 2026 per SRPT's latest filing, from $7.0 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $17.1 million in Q2 2024 and bottomed at $4.3 million in Q3 2022.
• The 5-year median for Other Accumulated Expenses is $10.2 million (2025), against an average of $9.9 million.
• Across the five-year window, Other Accumulated Expenses surged 228.94% in 2022 and plunged 70.43% in 2026, its largest moves.
• Year by year, Other Accumulated Expenses stood at $5.3 million in 2022, then jumped by 127.14% to $12.1 million in 2023, then increased by 11.62% to $13.5 million in 2024, then plunged by 48.3% to $7.0 million in 2025, then sank by 33.51% to $4.6 million in 2026.
• Per Business Quant, the three latest SRPT Other Accumulated Expenses figures stand at $4.6 million (Q1 2026), $7.0 million (Q4 2025), and $10.2 million (Q3 2025).